<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?npg-journal-abbreviation?><?properties open_access?><?DTDIdentifier.IdentifierValue -//NPGSJ//DTD full length article DTD version 7.0 XML//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ajarticle_v7_x.dtd?><?SourceDTD.Version 7.0?><?ConverterInfo.XSLTName naturesa2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacogenomics J</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacogenomics J</journal-id><journal-title-group><journal-title>The Pharmacogenomics Journal</journal-title></journal-title-group><issn pub-type="ppub">1470-269X</issn><issn pub-type="epub">1473-1150</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5817390</article-id><article-id pub-id-type="pii">tpj201682</article-id><article-id pub-id-type="doi">10.1038/tpj.2016.82</article-id><article-id pub-id-type="pmid">27897269</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running">ABCB1 and SLCO1B1 variants and edoxaban exposure</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vandell</surname><given-names>A G</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rubets</surname><given-names>I</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>K S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Walker</surname><given-names>J R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1"><label>1</label><institution>Translational Medicine &amp; Clinical Pharmacology, Daiichi Sankyo Pharma Development</institution>, Edison, NJ, <country>USA</country></aff><aff id="aff2"><label>2</label><institution>Pharsight Consulting Services</institution>, Montreal, Quebec, <country>Canada</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label><institution>Translational Medicine &amp; Clinical Pharmacology, Daiichi Sankyo Pharma Development</institution>, 399 Thornall St, Edison, NJ 08837, <country>USA</country>. E-mail: <email>avandell@dsi.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>01</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>29</day><month>11</month><year>2016</year></pub-date><volume>18</volume><issue>1</issue><fpage>153</fpage><lpage>159</lpage><history><date date-type="received"><day>24</day><month>02</month><year>2016</year></date><date date-type="rev-recd"><day>01</day><month>07</month><year>2016</year></date><date date-type="accepted"><day>31</day><month>08</month><year>2016</year></date></history><permissions><copyright-statement>Copyright © 2018 The Author(s)</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>The Author(s)</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</ext-link></license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>Edoxaban and its low-abundance, active metabolite M4 are substrates of P-glycoprotein (P-gp; MDR1) and organic anion transporter protein 1B1 (OATP1B1), respectively, and pharmacological inhibitors of P-gp and OATP1B1 can affect edoxaban and M4 pharmacokinetics (PK). </plain></SENT>
<SENT sid="2" pm="."><plain>In this integrated pharmacogenomic analysis, genotype and concentration–time data from 458 healthy volunteers in 14 completed phase 1 studies were pooled to examine the impact on edoxaban PK parameters of allelic variants of ABCB1 (rs1045642: C3435T) and SLCO1B1 (rs4149056: T521C), which encode for P-gp and OATP1B1. </plain></SENT>
<SENT sid="3" pm="."><plain>Although some pharmacologic inhibitors of P-gp and OATP1B1 increase edoxaban exposure, neither the ABCB1 C3435T nor the SLCO1B1 T521C polymorphism affected edoxaban PK. </plain></SENT>
<SENT sid="4" pm="."><plain>A slight elevation in M4 exposure was observed among SLCO1B1 C-allele carriers; however, this elevation is unlikely to be clinically significant as plasma M4 concentrations comprise &lt;10% of total edoxaban levels. </plain></SENT>
</text></SecTag></p></abstract></article-meta></front><body><SecTag type="INTRO"><sec><title><text><SENT sid="5" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="6" pm="."><plain>Edoxaban is a once-daily, orally administered, selective and direct inhibitor of factor Xa, a key mediator of both the intrinsic and extrinsic pathways of the clotting cascade.1, 2 By binding to free Xa as well as Xa bound to the prothrombinase complex, edoxaban attenuates thrombin generation, and consequently, thrombus formation.1, 2 Edoxaban is approved in Japan for the prevention of venous thromboembolism (VTE) following major orthopedic surgery.3 Based on the results of 2 large clinical trials,4, 5 edoxaban recently received approval for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and the treatment of venous thromboembolism in Japan,6 the United States,7 Switzerland8 and the European Union.9 </plain></SENT>
</text></p><p><text><SENT sid="7" pm="."><plain>Edoxaban is a substrate of the efflux pump P-glycoprotein (P-gp; also known as multidrug resistance protein 1 or MDR1) and its metabolite M4 is a substrate of the hepatic uptake transporter organic anion transporter protein 1B1 (OATP1B1), as demonstrated in in vitro studies.10 Drug–drug interaction studies have demonstrated that changes in transporter function may influence edoxaban and M4 exposure in a clinically significant manner. </plain></SENT>
<SENT sid="8" pm="."><plain>P-gp inhibitors, including quinidine and verapamil, increased edoxaban exposure in healthy subjects and in nonvalvular atrial fibrillation patients.11, 12 Cyclosporine, which inhibits several transporters including OATP1B1, and rifampin increase M4 levels in healthy volunteers.13, 14 </plain></SENT>
</text></p><p><text><SENT sid="9" pm="."><plain>Genetic variations in ABCB1 (ATP-binding cassette, sub-family B, member 1) and SLCO1B1 (solute carrier organic anion transporter family, member 1B1), the genes that encode for P-gp and OATP1B1, respectively, are known to affect transporter function and thus substrate exposure. </plain></SENT>
<SENT sid="10" pm="."><plain>In particular, studies have indicated that a single-nucleotide polymorphism (SNP) in ABCB1, rs1045642—a C to T substitution at position 3435 of the coding sequence—alters P-gp expression and may affect the pharmacokinetics (PK) of some P-gp substrates, although reports regarding the nature of the effect are conflicting.15, 16 Similarly, the SLCO1B1 polymorphism, rs4149056—a T to C substitution at position 521 of the coding sequence—is associated with reduced transporter activity; augments exposure of OATP1B1 substrates such as atorvastatin, rosuvastatin and pravastatin;17, 18 and is associated with increased risk of statin-induced myalgia and rhabdomyolysis.19 </plain></SENT>
</text></p><p><text><SENT sid="11" pm="."><plain>Edoxaban undergoes minimal metabolism as nearly 73% of the absorbed drug is eliminated unmodified.20 M4 (also known as D21-2393), which has anticoagulant properties similar to edoxaban (data on file), is a low-abundance, active metabolite of edoxaban, accounting for &lt;10% of the total anticoagulant exposure.20 The metabolic enzyme, carboxylesterase 1 (CES1), catalyzes the formation of M4 from edoxaban.20 The terminal half-life of edoxaban ranges from 10 to 14 h,21 and ~50% of the absorbed dose is renally eliminated.20, 22 The in vitro plasma protein binding of edoxaban and M4 are ~55% and 80%, respectively.21, 23 </plain></SENT>
</text></p><p><text><SENT sid="12" pm="."><plain>Although increased edoxaban and M4 exposures are observed upon administration of the P-gp inhibitors quinidine and verapamil or the OATP1B1 inhibitor cyclosporine, the effects of common genetic variants that alter the function of these transporters on edoxaban and M4 PK are unknown. </plain></SENT>
<SENT sid="13" pm="."><plain>To answer these questions, a prospective-retrospective integrated analysis using pooled genotype and PK data from 14 completed edoxaban phase 1 studies was conducted. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec><title><text><SENT sid="14" pm="."><plain>Materials and methods </plain></SENT>
</text></title><sec><title><text><SENT sid="15" pm="."><plain>Analysis design and population selection </plain></SENT>
</text></title><p><text><SENT sid="16" pm="."><plain>Twenty-four phase 1 edoxaban studies were considered for inclusion in the present integrated analysis. </plain></SENT>
<SENT sid="17" pm="."><plain>Completed studies were included in the current analysis provided they enrolled healthy subjects, included a treatment arm in which a single 60-mg edoxaban dose was administered under fasting conditions, and collected DNA samples that were available for genotyping. </plain></SENT>
<SENT sid="18" pm="."><plain>Only data from the edoxaban 60 mg treatment groups, in which edoxaban was administered alone and not with any potentially interacting drugs or food, were included in the analysis. </plain></SENT>
<SENT sid="19" pm="."><plain>Based on these criteria, DNA samples and PK data from 458 healthy subjects (365 males and 93 females) from 14 completed edoxaban phase 1 clinical studies were pooled for this analysis (Supplementary Table 1). </plain></SENT>
<SENT sid="20" pm="."><plain>All subjects provided written informed consent to participate in the clinical studies and supply genetic material. </plain></SENT>
<SENT sid="21" pm="."><plain>Each study was approved by an institutional review board and was carried out in compliance with the Declaration of Helsinki and the International Conference on Harmonisation. </plain></SENT>
</text></p><p><text><SENT sid="22" pm="."><plain>For each of the included phase 1 studies, serial blood samples were collected at predose and up to 96 h postdose to determine edoxaban and M4 plasma concentrations in accordance with the specific study protocols. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="23" pm="."><plain>Bioanalytic methods </plain></SENT>
</text></title><p><text><SENT sid="24" pm="."><plain>Edoxaban and M4 plasma concentrations were measured by a validated liquid chromatography tandem mass spectrometry (LC–MS/MS) method for all studies by Advion BioServices (Ithaca, New York, USA). </plain></SENT>
<SENT sid="25" pm="."><plain>The lower limit of quantitation for edoxaban and M4 was 0.764 ng ml−1 and 0.0792 ng ml−1, respectively. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="26" pm="."><plain>Genotype analysis </plain></SENT>
</text></title><p><text><SENT sid="27" pm="."><plain>Validated commercial Taqman assays (Life Technologies, Waltham, MA, USA) were performed to determine ABCB1 rs1045642 and SLCO1B1 rs4149056 genotypes by Gentris Corporation (Morrisville, North Carolina, USA). </plain></SENT>
<SENT sid="28" pm="."><plain>Assays were carried out in duplicate. </plain></SENT>
<SENT sid="29" pm="."><plain>If results were not in agreement, the sample was genotyped using Sanger sequencing. </plain></SENT>
<SENT sid="30" pm="."><plain>Results were further confirmed by reanalyzing ~25 (~5%) randomly selected samples for both genotypes using Sanger sequencing in both the forward and reverse direction. </plain></SENT>
<SENT sid="31" pm="."><plain>Using this approach, the genotype call rate was 100%. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="32" pm="."><plain>Pharmacokinetic and statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="33" pm="."><plain>An integrated database consisting of PK parameters and genotype data from each of the 458 subjects included in this analysis was created. </plain></SENT>
<SENT sid="34" pm="."><plain>The PK parameters AUCinf, AUC0–24, AUClast, Cmax, and C24 were computed using a noncompartmental approach with WinNonlin Professional software Version 4.0 or 5.2 (Pharsight Corporation, Montreal, Canada). </plain></SENT>
<SENT sid="35" pm="."><plain>PK parameters were statistically compared between genotypes using analysis of variance (ANOVA) in SAS Proc MIXED (SAS Institute, Cary, North Carolina, USA), with genotype and study ID as fixed effects. </plain></SENT>
<SENT sid="36" pm="."><plain>Point estimates and 90% confidence intervals (CI) for the ratios of the PK parameters between different allele variations of ABCB1 rs1045642 (CC vs CT, CC vs TT, and CT vs TT) and SLCO1B1 rs4149056 (C-carriers vs TT) were calculated using multiple pairwise comparisons by applying exponential transformation to the difference in least squares (LS) means calculated using ln-transformed values and CIs obtained from the ANOVA model. </plain></SENT>
</text></p><p><text><SENT sid="37" pm="."><plain>Assuming the expected mean ratio was within the range of 95% to 105% with Bonferroni adjustment for multiple comparisons among the three rs1045642 variant subgroups, a genotype subgroup of at least 37, 105 and 98 subjects for edoxaban AUCinf, Cmax and C24, respectively, was required in order to have at least 80% power so that the 90% CI for the mean ratio would fall within the range of 80–125%. </plain></SENT>
<SENT sid="38" pm="."><plain>Using similar criteria, rs4149056 genotype subgroups required a minimum of 26, 75 and 70 subjects for edoxaban AUCinf, Cmax and C24, respectively, while the corresponding PK measures for M4 required 57, 103 and 96 subjects, respectively. </plain></SENT>
<SENT sid="39" pm="."><plain>PK parameters were not considered to be different between genotype groups if the 90% CIs for the geometric LS means ratios of the analysis groups were within the range of 80–125%. </plain></SENT>
</text></p><p><text><SENT sid="40" pm="."><plain>The metabolite-to-parent ratios (MPRs) were calculated for AUClast, AUCinf and Cmax with adjustments for molecular weights and summarized by SLCO1B1 rs4149056 genotype (TT and C-carriers). </plain></SENT>
<SENT sid="41" pm="."><plain>The molecular weights used in the MPR calculations were 548.07 g mol−1 for edoxaban (parent) and 520.99 g mol−1 for the metabolite M4. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec><title><text><SENT sid="42" pm="."><plain>Results </plain></SENT>
</text></title><sec><title><text><SENT sid="43" pm="."><plain>Demographics and baseline characteristics </plain></SENT>
</text></title><p><text><SENT sid="44" pm="."><plain>The demographics and baseline characteristics of subjects included in this analysis are listed by ABCB1 and SLCO1B1 genotype in Table 1. </plain></SENT>
<SENT sid="45" pm="."><plain>The mean age, body mass index, and renal function were similar across genotype groups. </plain></SENT>
<SENT sid="46" pm="."><plain>The ABCB1 and SLCO1B1 SNPs were in Hardy–Weinberg equilibrium for all race groups examined. </plain></SENT>
<SENT sid="47" pm="."><plain>The observed frequency of ABCB1 genotypes varied across ethnic groups, consistent with previously published findings.24 </plain></SENT>
</text></p><p><text><SENT sid="48" pm="."><plain>Due to the infrequent occurrence of SLCO1B1 CC homozygotes (0.66%) in the overall population, subjects with the CT or CC genotypes were combined together and analyzed as C-carriers. </plain></SENT>
<SENT sid="49" pm="."><plain>Thus, overall, 16.2% of subjects were C-carriers, and 83.8% of subjects were TT homozygotes. </plain></SENT>
<SENT sid="50" pm="."><plain>As previously reported in the literature, the frequency of SLCO1B1 T521C variants differed between races.25 </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="51" pm="."><plain>Pharmacokinetic parameters </plain></SENT>
</text></title><p><text><SENT sid="52" pm="."><plain>As shown in Figure 1a, ABCB1 genotype did not significantly alter mean plasma edoxaban concentration–time curves. </plain></SENT>
<SENT sid="53" pm="."><plain>Edoxaban PK parameters including total plasma exposure (AUCinf), peak (Cmax) and trough plasma concentrations (C24) were not affected by ABCB1 C3435T genotype (Figures 1b–d and Table 2). </plain></SENT>
<SENT sid="54" pm="."><plain>In addition, plasma exposure from the time of dosing to the last measurable concentration (AUClast) and plasma exposure up to 24 h after dosing (AUC0–24) exhibited a similar range of values across genotypes (Table 2). </plain></SENT>
<SENT sid="55" pm="."><plain>The values of ratios of geometric LS means for AUCinf, Cmax and C24 were 103.5 (90% CI, 98.2–109.1), 109.8 (90% CI, 100.3–120.2), and 93.4 (90% CI, 85.7–101.9), respectively, for a CT vs CC comparison, and 104.9 (90% CI, 96.8–113.6), 106.2 (90% CI, 92.6–121.8), and 92.3 (90% CI, 80.8–105.4), respectively, for a TT vs CC comparison. </plain></SENT>
<SENT sid="56" pm="."><plain>These data reveal that the ABCB1 C3435T SNP does not significantly affect edoxaban exposure. </plain></SENT>
</text></p><p><text><SENT sid="57" pm="."><plain>The mean plasma concentration vs time profiles of edoxaban were also comparable among subjects independent of SLCO1B1 genotype (Figure 2a, left panel). </plain></SENT>
<SENT sid="58" pm="."><plain>Consistent with this observation, AUCinf, Cmax, and C24 of edoxaban were similar between C-carriers and TT homozygotes (Figure 2b and Table 3). </plain></SENT>
<SENT sid="59" pm="."><plain>Furthermore, the range of values for AUClast and AUC0–24 did not differ between C-carriers and TT homozygotes (Table 3). </plain></SENT>
<SENT sid="60" pm="."><plain>In comparing C-carriers vs TT homozygotes, the geometric LS means ratios for edoxaban AUCinf, Cmax and C24 were 101.0 (90% CI, 95.9–106.3), 105.4 (90% CI, 96.5–115.1) and 95.3 (90% CI, 87.5–103.7), respectively. </plain></SENT>
</text></p><p><text><SENT sid="61" pm="."><plain>Plasma M4 exposure was slightly higher among SLCO1B1 C-carriers compared to TT homozygotes, as assessed by the mean plasma concentration vs time curves of M4 (Figure 2a, right panel). </plain></SENT>
<SENT sid="62" pm="."><plain>Accordingly, C-carriers exhibited modestly higher levels of median total exposure and peak plasma concentration (Figure 2c). </plain></SENT>
<SENT sid="63" pm="."><plain>Median M4 trough levels were comparable between the 2 genotypes (Figure 2c), while mean AUClast and AUC0–24 values were greater among C-carriers than TT homozygotes (Table 3). </plain></SENT>
<SENT sid="64" pm="."><plain>The geometric LS means ratios comparing C-carriers with TT homozygotes for AUCinf, Cmax and C24 were 126.9 (90% CI, 117.4–137.1), 124.1 (90% CI, 111.9–137.5) and 114.9 (90% CI, 104.0–127.0), respectively; the 90% CI of the ratios of geometric LS means of C-carriers vs TT homozygotes exceeded the predefined bioequivalence range (90% CI, 80–125%) for each of these PK measures. </plain></SENT>
<SENT sid="65" pm="."><plain>Taken together, these data confirm that while the SLCO1B1 T521C SNP does not influence edoxaban exposure, M4 exposure is elevated among C-carriers. </plain></SENT>
</text></p><p><text><SENT sid="66" pm="."><plain>Edoxaban and M4 have similar anticoagulant activities on a molar basis (data on file). </plain></SENT>
<SENT sid="67" pm="."><plain>MPRs for AUClast, AUCinf and Cmax of M4 to edoxaban ranged from 9% to 11%, indicating that M4 contributes a small amount to the overall anticoagulant effect (Table 3 and Figure 3). </plain></SENT>
<SENT sid="68" pm="."><plain>Together, these findings demonstrate that the SLCO1B1 T521C polymorphism increases M4 exposure, but not in a clinically meaningful way, as M4 plasma concentration is approximately one-tenth that of edoxaban. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="69" pm="."><plain>Safety </plain></SENT>
</text></title><p><text><SENT sid="70" pm="."><plain>The single 60-mg dose of edoxaban was generally well tolerated by the healthy subjects in these 14 phase 1 studies.13, 14, 26, 27, 28, 29 </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec><title><text><SENT sid="71" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="72" pm="."><plain>Common genetic variants and pharmacologic inhibition can result in altered transporter function, and thereby affect the PK of certain substrates. </plain></SENT>
<SENT sid="73" pm="."><plain>Allelic variants of ABCB1, including C3435T, which codes for a synonymous substitution in exon 26, are reported to alter the disposition of some P-gp substrates.15, 24, 30, 31 For example, some reports indicate that exposure to digoxin, a P-gp substrate, is altered upon the administration of the P-gp inhibitor quinidine32 and is affected by the ABCB1 C3435T SNP.15, 30, 31 The SLCO1B1 T521C SNP results in a valine-to-alanine substitution in the uptake transporter OATP1B1, leading to decreased membrane expression33 and transport activity of OATP1B1.19, 34, 35 Concentrations of the OATP1B1 substrate rosuvastatin increase upon treatment with the OATP1B1 inhibitor cyclosporine36 and are also higher among SLCO1B1 T521C CC homozygotes than TT homozygotes.18 </plain></SENT>
</text></p><p><text><SENT sid="74" pm="."><plain>Edoxaban is a substrate of the P-gp, and exposure to edoxaban increases upon coadministration of the P-gp inhibitors ketoconazole, quinidine, erythromycin, verapamil or dronedarone in both healthy subjects and nonvalvular atrial fibrillation patients.11, 12 M4, an active metabolite of edoxaban, is a substrate of OATP1B1,10 and coadministration of edoxaban with the OATP1B1 inhibitor cyclosporine increases exposure to M4.13 </plain></SENT>
</text></p><p><text><SENT sid="75" pm="."><plain>The present integrated analysis pooled PK and genotype data from 14 completed single-dose, phase 1 studies involving 458 healthy subjects to examine the impact of polymorphisms in two important transporter genes on edoxaban exposure. </plain></SENT>
<SENT sid="76" pm="."><plain>Results from this analysis demonstrate for the first time that common genetic variants of ABCB1 (C3435T) and SLCO1B1 (T521C) had minimal impact on edoxaban exposure. </plain></SENT>
<SENT sid="77" pm="."><plain>Edoxaban concentration–time profiles were comparable regardless of ABCB1 C3435T genotype. </plain></SENT>
<SENT sid="78" pm="."><plain>In addition, mean and median AUCinf, Cmax and C24 of edoxaban did not vary between the three ABCB1 genotypes. </plain></SENT>
<SENT sid="79" pm="."><plain>With regard to the SLCO1B1 T521C genotype, edoxaban concentration–time profiles and median PK parameters including AUCinf, Cmax and C24 were similar between TT homozygotes and C-carriers. </plain></SENT>
<SENT sid="80" pm="."><plain>This was expected as edoxaban is not known to be an OATP1B1 substrate. </plain></SENT>
<SENT sid="81" pm="."><plain>While a modest increase in M4 plasma exposure is observed among C-allele carriers, this association is unlikely to be clinically relevant given that M4, at concentrations reaching &lt;10% of edoxaban levels, does not significantly contribute to the total anticoagulant activity. </plain></SENT>
<SENT sid="82" pm="."><plain>Therefore, while some pharmacologic inhibitors of P-gp and OATP1B1 may increase edoxaban and M4 exposure in a clinically relevant way,11, 12, 13 these two common polymorphisms do not. </plain></SENT>
</text></p><p><text><SENT sid="83" pm="."><plain>As concurrent administration of P-gp or OATP1B1 inhibitors with edoxaban increases edoxaban or M4 exposure, respectively, the effects of functional polymorphisms of ABCB1 and SLCO1B1 on edoxaban exposure were tested in this study. </plain></SENT>
<SENT sid="84" pm="."><plain>Neither ABCB1 C3435T nor SLCO1B1 T521C genotype status affected the exposure of edoxaban among healthy subjects, suggesting that these are not clinically significant polymorphisms. </plain></SENT>
<SENT sid="85" pm="."><plain>As such, the data reported here suggest that prescribers can follow approved dosing recommendations21 for edoxaban without concern for the presence of these two genetic variants. </plain></SENT>
</text></p><p><text><SENT sid="86" pm="."><plain>This study was limited to candidate SNPs and thus did not capture the effects of other known ABCB1 and SLCO1B1 polymorphisms or of haplotypes24, 25 on edoxaban and M4 PK. </plain></SENT>
<SENT sid="87" pm="."><plain>The polymorphisms chosen for this analysis are common, well characterized, and known to be functionally active24, 25 and thus were selected for initial pharmacogenomic signal detection. </plain></SENT>
<SENT sid="88" pm="."><plain>Because of the lack of an observed effect with these polymorphisms, additional SNPs and haplotypes within ABCB1 and SLCO1B1 were not characterized, as they are unlikely to have a substantial impact on edoxaban or M4 PK. </plain></SENT>
</text></p><p><text><SENT sid="89" pm="."><plain>In pharmacogenomics, integrated multistudy analyses can be especially useful to answer important questions that otherwise cannot be resolved within small individual studies. </plain></SENT>
<SENT sid="90" pm="."><plain>Some phase 1 studies—which characterize the PK parameters of new drugs and investigate the effects of food and potential interacting drugs on those PK parameters—include pharmacogenomics sample collection, although their typically small sample size limits the investigation of pharmacogenomic effects. </plain></SENT>
<SENT sid="91" pm="."><plain>Although phases 2 and 3 studies are often sufficiently powered for pharmacogenomics analyses, these studies usually lack the comprehensive concentration–time data needed to explore potential pharmacogenomic effects on PK parameters. </plain></SENT>
<SENT sid="92" pm="."><plain>The current integrated analysis circumvents these limitations by pooling genetic and concentration–time data from multiple phase 1 studies. </plain></SENT>
<SENT sid="93" pm="."><plain>The resulting data set, containing genotypes, covariates, and full PK profiles, is large enough to conduct an adequately powered pharmacogenomic analysis of PK parameters. </plain></SENT>
<SENT sid="94" pm="."><plain>This approach has been successfully employed in previous studies to investigate the effects of CYP2C19 polymorphisms on the outcomes of clopidogrel treatment37 and UGT1A1 polymorphisms on dolutegravir PK.38 </plain></SENT>
</text></p><p><text><SENT sid="95" pm="."><plain>Variability can be introduced into pooled analyses when different laboratories are used to collect genotype or concentration–time data. </plain></SENT>
<SENT sid="96" pm="."><plain>For the present study, all genetic data were generated by a single genotyping laboratory and all concentration–time data were generated by a single bioanalysis laboratory. </plain></SENT>
<SENT sid="97" pm="."><plain>However, some limitations remain. </plain></SENT>
<SENT sid="98" pm="."><plain>First, SNPs in CES1, which is involved in the metabolism of edoxaban to M4, have previously been reported to affect the disposition of other drugs39, 40 but were not investigated in this study. </plain></SENT>
<SENT sid="99" pm="."><plain>In addition, while this analysis controlled for race, the effect of ABCB1 C3435T and SLCO1B1 T521C on edoxaban and M4 PK were not analyzed by race. </plain></SENT>
<SENT sid="100" pm="."><plain>The present study was adequately powered; however, its sample size limits further evaluation of the effect of race, additional polymorphisms, and haplotypes. </plain></SENT>
<SENT sid="101" pm="."><plain>Larger follow-up replication studies will be required to address the limitations of this analysis. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="AUTH_CONT"><ack><p>This integrated pharmacogenomic analysis was sponsored by Daiichi Sankyo, Inc. Writing and editorial support was provided by Sameera Kongara, PhD, of AlphaBioCom, LLC, and funded by Daiichi Sankyo. Dr Brown and Dr Walker were employees of Daiichi Sankyo when this work was conducted.</p><p><bold>Author contributions</bold></p><p>AGV, KB, JL, MS and JRW designed the study. IR performed the research. AGV, JL, IR and JRW analyzed data. All authors were involved in the development of the manuscript and provided approval for submission.</p></ack></SecTag><fn-group><SecTag type="SUPPL"><fn><p><text><SENT sid="102" pm="."><plain>Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website (http://www.nature.com/tpj) </plain></SENT>
</text></p></fn></SecTag><fn fn-type="COI-statement"><p><text><SENT sid="103" pm="."><plain>AG Vandell, J Lee and M Shi are employees of Daiichi Sankyo. </plain></SENT>
<SENT sid="104" pm="."><plain>K Brown and JR Walker were employees of Daiichi Sankyo at the time the study was conducted. </plain></SENT>
<SENT sid="105" pm="."><plain>I Rubets is an employee of Pharsight Consulting Services. </plain></SENT>
</text></p></fn></fn-group><SecTag type="REF"><ref-list><ref id="bib1"><text><SENT sid="106" pm="."><plain>Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 2011; 62: 41–57.21226611 </plain></SENT>
</text></ref><ref id="bib2"><text><SENT sid="107" pm="."><plain>Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 2008; 6: 1542–1549.18624979 </plain></SENT>
</text></ref><ref id="bib3"><text><SENT sid="108" pm="."><plain>Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA (Edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery. </plain></SENT>
<SENT sid="109" pm="."><plain>Available at http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/005806.html. </plain></SENT>
<SENT sid="110" pm="."><plain>Accessed on 3 December 2014. </plain></SENT>
</text></ref><ref id="bib4"><text><SENT sid="111" pm="."><plain>Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093–2104.24251359 </plain></SENT>
</text></ref><ref id="bib5"><text><SENT sid="112" pm="."><plain>Hokusai VTE Investigators Buller HR Decousus H Grosso MA Mercuri M Middeldorp S et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406–1415.23991658 </plain></SENT>
</text></ref><ref id="bib6"><text><SENT sid="113" pm="."><plain>Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA (edoxaban) in Japan. </plain></SENT>
<SENT sid="114" pm="."><plain>Available at http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006189.html. </plain></SENT>
<SENT sid="115" pm="."><plain>Accessed on 3 December 2014. </plain></SENT>
</text></ref><ref id="bib7"><text><SENT sid="116" pm="."><plain>U.S. </plain></SENT>
<SENT sid="117" pm="."><plain>FDA Approves Daiichi Sankyo’s Once-Daily SAVAYSA (edoxaban) Tablets for Reduction of Stroke Risk in Non-Valvular Atrial Fibrillation and for the Treatment of Venous Thromboembolism. </plain></SENT>
<SENT sid="118" pm="."><plain>Available at www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006236.html. </plain></SENT>
<SENT sid="119" pm="."><plain>Accessed on 14 January 2015. </plain></SENT>
</text></ref><ref id="bib8"><text><SENT sid="120" pm="."><plain>LIXIANA (edoxaban) approved in Switzerland. </plain></SENT>
<SENT sid="121" pm="."><plain>Available at http://www.daiichi-sankyo.eu/media/european-news/news-detail/article/lixianaR-edoxaban-approval-in-switzerland.html. </plain></SENT>
<SENT sid="122" pm="."><plain>Accessed on 16 April 2015. </plain></SENT>
</text></ref><ref id="bib9"><text><SENT sid="123" pm="."><plain>Daiichi Sankyo’s Once-Daily LIXIANA (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE. </plain></SENT>
<SENT sid="124" pm="."><plain>Available at http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006314.html. </plain></SENT>
<SENT sid="125" pm="."><plain>Accessed on 25 June 2015. </plain></SENT>
</text></ref><ref id="bib10"><text><SENT sid="126" pm="."><plain>Mikkaichi T, Yoshigae Y, Masumoto H, Imaoka T, Rozehnal V, Fischer T et al. Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition. Drug Metab Dispos 2014; 42: 520–528.24459178 </plain></SENT>
</text></ref><ref id="bib11"><text><SENT sid="127" pm="."><plain>Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 2013; 13: 331–342.23784266 </plain></SENT>
</text></ref><ref id="bib12"><text><SENT sid="128" pm="."><plain>Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 2012; 107: 925–936.22398655 </plain></SENT>
</text></ref><ref id="bib13"><text><SENT sid="129" pm="."><plain>Matsushima N, Zahir H, Mendell J, Chen S, He L, Parasrampuria D. Coadministration of Cyclosporine Increased Edoxaban Exposure in Healthy Adults. </plain></SENT>
<SENT sid="130" pm="."><plain>2014 American College of Clinical Pharmacology annual meeting September 14–16 Atlanta, Georgia. Clin Pharm Drug Dev 2014; 3: 1–59. </plain></SENT>
</text></ref><ref id="bib14"><text><SENT sid="131" pm="."><plain>Mendell J, Chen S, He L, Desai M, Parasramupria DA. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. Clin Drug Invest 2015; 35: 447–453. </plain></SENT>
</text></ref><ref id="bib15"><text><SENT sid="132" pm="."><plain>Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473–3478.10716719 </plain></SENT>
</text></ref><ref id="bib16"><text><SENT sid="133" pm="."><plain>Bonhomme-Faivre L, Devocelle A, Saliba F, Chatled S, Maccario J, Farinotti R et al. MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Transplantation 2004; 78: 21–25.15257034 </plain></SENT>
</text></ref><ref id="bib17"><text><SENT sid="134" pm="."><plain>Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003; 73: 554–565.12811365 </plain></SENT>
</text></ref><ref id="bib18"><text><SENT sid="135" pm="."><plain>Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007; 82: 726–733.17473846 </plain></SENT>
</text></ref><ref id="bib19"><text><SENT sid="136" pm="."><plain>Gong IY, Kim RB. Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet 2013; 28: 4–18.23047721 </plain></SENT>
</text></ref><ref id="bib20"><text><SENT sid="137" pm="."><plain>Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos 2012; 40: 2250–2255.22936313 </plain></SENT>
</text></ref><ref id="bib21"><text><SENT sid="138" pm="."><plain>SAVAYSA (edoxaban) Tablets for Oral Use. </plain></SENT>
<SENT sid="139" pm="."><plain>Full Prescribing Information. </plain></SENT>
<SENT sid="140" pm="."><plain>Parsippany, New Jersey. </plain></SENT>
<SENT sid="141" pm="."><plain>Daiichi Sankyo, Inc 2015. </plain></SENT>
</text></ref><ref id="bib22"><text><SENT sid="142" pm="."><plain>Matsushima N, Lee F, Sato T, Weiss D, Mendell J. Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharm Drug Dev 2013; 2: 358–366. </plain></SENT>
</text></ref><ref id="bib23"><text><SENT sid="143" pm="."><plain>Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet 2015; 55: 641–655. </plain></SENT>
</text></ref><ref id="bib24"><text><SENT sid="144" pm="."><plain>Ieiri I. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab Pharmacokinet 2012; 27: 85–105.22123128 </plain></SENT>
</text></ref><ref id="bib25"><text><SENT sid="145" pm="."><plain>Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011; 63: 157–181.21245207 </plain></SENT>
</text></ref><ref id="bib26"><text><SENT sid="146" pm="."><plain>Mendell J, Lee F, Chen S, Worland V, Shi M, Samama MM. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. J Cardiovasc Pharmacol 2013; 62: 212–221.23615159 </plain></SENT>
</text></ref><ref id="bib27"><text><SENT sid="147" pm="."><plain>Zahir H, Matsushima N, Halim AB, He L, Zhang G, Lee F et al. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects. Thromb Haemost 2012; 108: 166–175.22628060 </plain></SENT>
</text></ref><ref id="bib28"><text><SENT sid="148" pm="."><plain>Brown KS, Wickremasingha P, Parasrampuria D, Dishy V, Kochan J, Weiss D et al. The impact of prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban. J Am Coll Cardiol 2014; 63 (12_S). . </plain></SENT>
</text></ref><ref id="bib29"><text><SENT sid="149" pm="."><plain>Zahir H, Mendell J, Jin J, He L, Parasrampuria D. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of edoxaban in healthy adults. </plain></SENT>
<SENT sid="150" pm="."><plain>2014 American College of Clinical Pharmacology annual meeting September 14–16 Atlanta, Georgia. Clin Pharm Drug Dev 2014; 3: 1–59. </plain></SENT>
</text></ref><ref id="bib30"><text><SENT sid="151" pm="."><plain>Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001; 18: 1400–1404.11697464 </plain></SENT>
</text></ref><ref id="bib31"><text><SENT sid="152" pm="."><plain>Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 2003; 58: 809–812.12698307 </plain></SENT>
</text></ref><ref id="bib32"><text><SENT sid="153" pm="."><plain>Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA et al. Drug-drug interactions mediated through P-glycoprotein: clinical relevance, in vitro and in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 2009; 85: 173–181.18987624 </plain></SENT>
</text></ref><ref id="bib33"><text><SENT sid="154" pm="."><plain>Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001; 276: 35669–35675.11477075 </plain></SENT>
</text></ref><ref id="bib34"><text><SENT sid="155" pm="."><plain>Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006; 130: 1793–1806.16697742 </plain></SENT>
</text></ref><ref id="bib35"><text><SENT sid="156" pm="."><plain>Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 2005; 15: 513–522.15970799 </plain></SENT>
</text></ref><ref id="bib36"><text><SENT sid="157" pm="."><plain>Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004; 76: 167–177.15289793 </plain></SENT>
</text></ref><ref id="bib37"><text><SENT sid="158" pm="."><plain>Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304: 1821–1830.20978260 </plain></SENT>
</text></ref><ref id="bib38"><text><SENT sid="159" pm="."><plain>Chen SSt, Jean P, Borland J, Song I, Yeo AJ, Piscitelli S et al. Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics. Pharmacogenomics 2014; 15: 9–16.24329186 </plain></SENT>
</text></ref><ref id="bib39"><text><SENT sid="160" pm="."><plain>Lewis JP, Horenstein RB, Ryan K, O'Connell JR, Gibson Q, Mitchell BD et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics 2013; 23: 1–8.23111421 </plain></SENT>
</text></ref><ref id="bib40"><text><SENT sid="161" pm="."><plain>Pare G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013; 127: 1404–1412.23467860 </plain></SENT>
</text></ref></ref-list></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="sup1"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="xob1"><label>Supplementary Table 1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tpj201682x1.docx"><caption><p><text><SENT sid="162" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></back><floats-group><SecTag type="FIG"><fig id="fig1"><label>Figure 1</label><caption><p><text><SENT sid="163" pm="."><plain>The effect of the ABCB1 rs1045642 variant on edoxaban pharmacokinetics. </plain></SENT>
<SENT sid="164" pm="."><plain>(a) Mean concentration–time profiles by genotype. </plain></SENT>
<SENT sid="165" pm="."><plain>Box and whisker plots demonstrating the effect of ABCB1 rs1045642 genotypes on (b) AUCinf, (c) Cmax and (d) C24. </plain></SENT>
<SENT sid="166" pm="."><plain>Inset figure in (a) shows profile of interval from initial dosing to 12 h postdose. </plain></SENT>
<SENT sid="167" pm="."><plain>Error bars in (a) represent the standard deviation. </plain></SENT>
<SENT sid="168" pm="."><plain>Whiskers in (b, c and d) indicate the 10th and 90th percentiles; individual dots represent points outside of the 10th and 90th percentiles. </plain></SENT>
<SENT sid="169" pm="."><plain>Median values are represented numerically and as lines in box plots. </plain></SENT>
</text></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tpj201682f1"/></fig></SecTag><SecTag type="FIG"><fig id="fig2"><label>Figure 2</label><caption><p><text><SENT sid="170" pm="."><plain>The effect of the SLCO1B1 rs4149056 variant on edoxaban and M4 pharmacokinetics. </plain></SENT>
<SENT sid="171" pm="."><plain>Mean concentration–time profiles by genotype of (a) edoxaban (left panel) and M4 (right panel). </plain></SENT>
<SENT sid="172" pm="."><plain>Box and whisker plots demonstrating the effect of SLCO1B1 rs4149056 genotypes on AUCinf, Cmax and C24 for (b) edoxaban and (c) M4. </plain></SENT>
<SENT sid="173" pm="."><plain>Inset figure in (a) shows profile of interval from initial dosing to 12 h postdose. </plain></SENT>
<SENT sid="174" pm="."><plain>Error bars in (a) represent the standard deviation. </plain></SENT>
<SENT sid="175" pm="."><plain>Whiskers in (b and c) indicate the 10th and 90th percentiles; individual dots represent points outside of the 10th and 90th percentiles. </plain></SENT>
<SENT sid="176" pm="."><plain>Median values are represented numerically and as lines in box plots. </plain></SENT>
</text></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tpj201682f2"/></fig></SecTag><SecTag type="FIG"><fig id="fig3"><label>Figure 3</label><caption><p><text><SENT sid="177" pm="."><plain>Summary pharmacokinetics of edoxaban and M4 in plasma by SLCO1B1 rs4149056 genotype. </plain></SENT>
<SENT sid="178" pm="."><plain>Bar graphs represent mean values, and the error bars indicate standard deviation. </plain></SENT>
</text></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tpj201682f3"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="tbl1"><label>Table 1</label><caption><title>Demographic summary of <italic>ABCB1</italic> (rs1045642) and <italic>SLCO1B1</italic> (rs4149056) genotyped population</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><text><SENT sid="179" pm="."><plain>  </plain></SENT>
</text></th><th colspan="3" align="center" valign="top" charoff="50"><text><SENT sid="180" pm="."><plain>ABCB1 (rs1045642) </plain></SENT>
</text></th><th align="center" valign="top" charoff="50"><text><SENT sid="181" pm="."><plain>N=458 </plain></SENT>
</text></th><th colspan="3" align="center" valign="top" charoff="50"><text><SENT sid="182" pm="."><plain>SLCO1B1 (rs4149056) </plain></SENT>
</text></th></tr><tr><th align="left" valign="top" charoff="50"><text><SENT sid="183" pm="."><plain>  </plain></SENT>
</text></th><th align="center" valign="top" charoff="50"><text><SENT sid="184" pm="."><plain>CC (n=206) </plain></SENT>
</text></th><th align="center" valign="top" charoff="50"><text><SENT sid="185" pm="."><plain>CT (n=193) </plain></SENT>
</text></th><th align="center" valign="top" charoff="50"><text><SENT sid="186" pm="."><plain>TT (n=59) </plain></SENT>
</text></th><th align="center" valign="top" charoff="50"><text><SENT sid="187" pm="."><plain>  </plain></SENT>
</text></th><th align="center" valign="top" charoff="50"><text><SENT sid="188" pm="."><plain>TT (n=384) </plain></SENT>
</text></th><th align="center" valign="top" charoff="50"><text><SENT sid="189" pm="."><plain>CT (n=71) </plain></SENT>
</text></th><th align="center" valign="top" charoff="50"><text><SENT sid="190" pm="."><plain>CC (n=3) </plain></SENT>
</text></th></tr></thead><tbody valign="top"><tr><td colspan="8" align="left" valign="top" charoff="50"><text><SENT sid="191" pm="."><plain>Sex, n (%) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="192" pm="."><plain> Male </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="193" pm="."><plain>167 (81.1) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="194" pm="."><plain>150 (77.7) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="195" pm="."><plain>48 (81.4) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="196" pm="."><plain>365 (79.7) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="197" pm="."><plain>311 (81.0) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="198" pm="."><plain>53 (74.6) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="199" pm="."><plain>1 (33.3) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="200" pm="."><plain> Female </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="201" pm="."><plain>39 (18.9) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="202" pm="."><plain>43 (22.3) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="203" pm="."><plain>11 (18.6) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="204" pm="."><plain>93 (20.3) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="205" pm="."><plain>73 (19.0) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="206" pm="."><plain>18 (25.4) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="207" pm="."><plain>2 (66.7) </plain></SENT>
</text></td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><text><SENT sid="208" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><text><SENT sid="209" pm="."><plain>Race, n (%) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="210" pm="."><plain> American Indian/Alaskan </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="211" pm="."><plain>0 (0.0) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="212" pm="."><plain>2 (1.0) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="213" pm="."><plain>0 (0.0) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="214" pm="."><plain>2 (0.4) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="215" pm="."><plain>1 (0.3) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="216" pm="."><plain>1 (1.4) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="217" pm="."><plain>0 (0.0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="218" pm="."><plain> Asian </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="219" pm="."><plain>1 (0.5) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="220" pm="."><plain>6 (3.1) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="221" pm="."><plain>3 (5.1) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="222" pm="."><plain>10 (2.2) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="223" pm="."><plain>9 (2.3) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="224" pm="."><plain>1 (1.4) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="225" pm="."><plain>0 (0.0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="226" pm="."><plain> Black or African American </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="227" pm="."><plain>150 (72.8) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="228" pm="."><plain>91 (47.2) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="229" pm="."><plain>9 (15.3) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="230" pm="."><plain>250 (54.6) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="231" pm="."><plain>226 (58.9) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="232" pm="."><plain>24 (33.8) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="233" pm="."><plain>0 (0.0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="234" pm="."><plain> White </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="235" pm="."><plain>43 (20.9) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="236" pm="."><plain>89 (46.1) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="237" pm="."><plain>45 (76.3) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="238" pm="."><plain>177 (38.6) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="239" pm="."><plain>134 (34.9) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="240" pm="."><plain>40 (56.3) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="241" pm="."><plain>3 (100.0) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="242" pm="."><plain> Other </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="243" pm="."><plain>12 (5.8) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="244" pm="."><plain>5 (2.6) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="245" pm="."><plain>2 (3.4) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="246" pm="."><plain>19 (4.1) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="247" pm="."><plain>14 (3.6) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="248" pm="."><plain>5 (7.0) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="249" pm="."><plain>0 (0.0) </plain></SENT>
</text></td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><text><SENT sid="250" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><text><SENT sid="251" pm="."><plain>Ethnicity, n (%) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="252" pm="."><plain> Hispanic/Latino </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="253" pm="."><plain>38 (18.4) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="254" pm="."><plain>51 (26.4) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="255" pm="."><plain>16 (27.1) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="256" pm="."><plain>105 (22.9) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="257" pm="."><plain>84 (21.9) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="258" pm="."><plain>20 (28.2) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="259" pm="."><plain>1 (33.3) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="260" pm="."><plain> Not Hispanic/Latino </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="261" pm="."><plain>168 (81.6) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="262" pm="."><plain>142 (73.6) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="263" pm="."><plain>43 (72.9) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="264" pm="."><plain>353 (77.1) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="265" pm="."><plain>300 (78.1) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="266" pm="."><plain>51 (71.8) </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="267" pm="."><plain>2 (66.7) </plain></SENT>
</text></td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><text><SENT sid="268" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><text><SENT sid="269" pm="."><plain>Age (years) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="270" pm="."><plain> Mean±s.d. </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="271" pm="."><plain>32.1±7.4 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="272" pm="."><plain>30.2±6.9 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="273" pm="."><plain>30.9±8.5 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="274" pm="."><plain>31.1±7.4 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="275" pm="."><plain>31.4±7.4 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="276" pm="."><plain>29.6±6.9 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="277" pm="."><plain>29.3±12.1 </plain></SENT>
</text></td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><text><SENT sid="278" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><text><SENT sid="279" pm="."><plain>Weight (kg) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="280" pm="."><plain> Mean±s.d. </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="281" pm="."><plain>81.5±12.1 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="282" pm="."><plain>79.0±12.1 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="283" pm="."><plain>76.6±12.0 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="284" pm="."><plain>79.8±12.2 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="285" pm="."><plain>80.1±12.1 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="286" pm="."><plain>78.8±12.3 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="287" pm="."><plain>64.0±4.0 </plain></SENT>
</text></td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><text><SENT sid="288" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><text><SENT sid="289" pm="."><plain>BMI (kg m−2) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="290" pm="."><plain> Mean±s.d. </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="291" pm="."><plain>26.6±3.1 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="292" pm="."><plain>25.9±3.0 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="293" pm="."><plain>25.2±3.0 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="294" pm="."><plain>26.1±3.1 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="295" pm="."><plain>26.1±3.0 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="296" pm="."><plain>26.2±3.2 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="297" pm="."><plain>24.9±3.9 </plain></SENT>
</text></td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><text><SENT sid="298" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td colspan="8" align="left" valign="top" charoff="50"><text><SENT sid="299" pm="."><plain>CLcr (ml min−1) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="300" pm="."><plain> Mean±s.d. </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="301" pm="."><plain>134.0±26.7 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="302" pm="."><plain>137.0±25.2 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="303" pm="."><plain>138.0±25.3 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="304" pm="."><plain>136.0±25.9 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="305" pm="."><plain>134.5±26.3 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="306" pm="."><plain>141.0±22.7 </plain></SENT>
</text></td><td align="center" valign="top" charoff="50"><text><SENT sid="307" pm="."><plain>146.7±25.2 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: BMI, body mass index; CL<sub>cr</sub>, creatinine clearance; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="tbl2"><label>Table 2</label><caption><title>Summary of pharmacokinetic parameters by <italic>ABCB1</italic> rs1045642 genotype</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="±"/><col align="char" char="."/><col align="char" char="±"/><col align="char" char="."/><col align="char" char="±"/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><text><SENT sid="308" pm="."><plain>Parameter </plain></SENT>
</text></th><th colspan="6" align="center" valign="top" char="±" charoff="50"><text><SENT sid="309" pm="."><plain>ABCB1 (rs1045642) genotypes </plain></SENT>
</text></th></tr><tr><th align="left" valign="top" charoff="50"><text><SENT sid="310" pm="."><plain>  </plain></SENT>
</text></th><th align="center" valign="top" char="±" charoff="50"><text><SENT sid="311" pm="."><plain>CC (n=206) </plain></SENT>
</text></th><th align="center" valign="top" char="." charoff="50"><text><SENT sid="312" pm="."><plain>n </plain></SENT>
</text></th><th align="center" valign="top" char="±" charoff="50"><text><SENT sid="313" pm="."><plain>CT (n=193) </plain></SENT>
</text></th><th align="center" valign="top" char="." charoff="50"><text><SENT sid="314" pm="."><plain>n </plain></SENT>
</text></th><th align="center" valign="top" char="±" charoff="50"><text><SENT sid="315" pm="."><plain>TT (n=59) </plain></SENT>
</text></th><th align="center" valign="top" char="." charoff="50"><text><SENT sid="316" pm="."><plain>n </plain></SENT>
</text></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><text><SENT sid="317" pm="."><plain>AUClast (ng•h ml−1) </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="318" pm="."><plain>1760±447.2 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="319" pm="."><plain>206 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="320" pm="."><plain>1814±417.0 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="321" pm="."><plain>193 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="322" pm="."><plain>1820±434.8 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="323" pm="."><plain>59 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="324" pm="."><plain>AUC0–24 (ng•h ml−1) </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="325" pm="."><plain>1608±441.2 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="326" pm="."><plain>206 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="327" pm="."><plain>1671±420.3 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="328" pm="."><plain>193 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="329" pm="."><plain>1680±441.5 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="330" pm="."><plain>59 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="331" pm="."><plain>AUCinf (ng•h ml−1) </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="332" pm="."><plain>1789±450.2 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="333" pm="."><plain>205 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="334" pm="."><plain>1845±417.8 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="335" pm="."><plain>190 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="336" pm="."><plain>1863±436.5 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="337" pm="."><plain>58 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="338" pm="."><plain>Cmax (ng ml−1) </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="339" pm="."><plain>246±96.6 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="340" pm="."><plain>206 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="341" pm="."><plain>268±95.2 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="342" pm="."><plain>193 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="343" pm="."><plain>261±101.3 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="344" pm="."><plain>59 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="345" pm="."><plain>C24 (ng ml−1) </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="346" pm="."><plain>12.5±5.11 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="347" pm="."><plain>205 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="348" pm="."><plain>11.8±5.07 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="349" pm="."><plain>193 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="350" pm="."><plain>12.3±6.46 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="351" pm="."><plain>58 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>Abbreviations: AUC, area under the curve; AUC<sub>0–24</sub>, AUC from the time of dosing over a 0–24 h postdose time interval; C<sub>24</sub>, observed plasma concentration at 24 h postdose; AUC<sub>inf</sub>, AUC from the time of dosing to the last measurable concentration and extrapolated to infinity; AUC<sub>last</sub>, area under the plasma drug concentration–time curve from the time of dosing to the last measurable concentration; <italic>C</italic><sub>max</sub>, maximum observed plasma concentration.</p></fn><fn id="t2-fn2"><p>Data presented as mean±s.d.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="tbl3"><label>Table 3</label><caption><title>Summary of pharmacokinetic parameters of edoxaban and M4 by <italic>SLCO1B1</italic> rs4149056 genotype</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="±"/><col align="char" char="."/><col align="char" char="±"/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th colspan="5" align="left" valign="top" charoff="50"><text><SENT sid="352" pm="."><plain>SLCO1B1 (rs4149056) genotypes </plain></SENT>
</text></th></tr><tr><th align="left" valign="top" charoff="50"><text><SENT sid="353" pm="."><plain>PK parameter </plain></SENT>
</text></th><th align="center" valign="top" char="±" charoff="50"><text><SENT sid="354" pm="."><plain>TT </plain></SENT>
</text></th><th align="center" valign="top" char="." charoff="50"><text><SENT sid="355" pm="."><plain>n </plain></SENT>
</text></th><th align="center" valign="top" char="±" charoff="50"><text><SENT sid="356" pm="."><plain>C-carriers </plain></SENT>
</text></th><th align="center" valign="top" char="." charoff="50"><text><SENT sid="357" pm="."><plain>n </plain></SENT>
</text></th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50"><text><SENT sid="358" pm="."><plain>Edoxaban </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="359" pm="."><plain> AUClast (ng • h ml−1) </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="360" pm="."><plain>1792.9±442.8 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="361" pm="."><plain>384 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="362" pm="."><plain>1777.2±380.8 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="363" pm="."><plain>74 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="364" pm="."><plain> AUC0–24 (ng • h ml−1) </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="365" pm="."><plain>1644.1±440.6 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="366" pm="."><plain>384 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="367" pm="."><plain>1643.8±392.9 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="368" pm="."><plain>74 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="369" pm="."><plain> AUCinf (ng • h ml−1) </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="370" pm="."><plain>1823.5±444.9 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="371" pm="."><plain>381 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="372" pm="."><plain>1815.5±382.4 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="373" pm="."><plain>72 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="374" pm="."><plain> Cmax (ng ml−1) </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="375" pm="."><plain>255.1±97.4 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="376" pm="."><plain>384 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="377" pm="."><plain>268.0±94.7 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="378" pm="."><plain>74 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="379" pm="."><plain> C24 (ng ml−1) </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="380" pm="."><plain>12.3±5.4 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="381" pm="."><plain>382 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="382" pm="."><plain>11.6±4.8 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="383" pm="."><plain>74 </plain></SENT>
</text></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><text><SENT sid="384" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><text><SENT sid="385" pm="."><plain>M4 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="386" pm="."><plain> AUClast (ng • h ml−1) </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="387" pm="."><plain>147.1±60.7 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="388" pm="."><plain>384 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="389" pm="."><plain>184.6±75.6 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="390" pm="."><plain>74 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="391" pm="."><plain> AUC0–24 (ng • h ml−1) </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="392" pm="."><plain>134.7±57.2 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="393" pm="."><plain>384 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="394" pm="."><plain>170.0±73.0 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="395" pm="."><plain>74 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="396" pm="."><plain> AUCinf (ng • h ml−1) </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="397" pm="."><plain>150.2±61.4 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="398" pm="."><plain>379 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="399" pm="."><plain>191.9±76.4 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="400" pm="."><plain>72 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="401" pm="."><plain> Cmax (ng ml−1) </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="402" pm="."><plain>21.2±10.7 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="403" pm="."><plain>384 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="404" pm="."><plain>26.7±13.6 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="405" pm="."><plain>74 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="406" pm="."><plain> C24 (ng ml−1) </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="407" pm="."><plain>1.1±0.57 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="408" pm="."><plain>382 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="409" pm="."><plain>1.3±0.74 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="410" pm="."><plain>74 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="411" pm="."><plain> MPR AUClast </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="412" pm="."><plain>8.7±2.9 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="413" pm="."><plain>384 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="414" pm="."><plain>10.9±3.6 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="415" pm="."><plain>74 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="416" pm="."><plain> MPR AUCinf </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="417" pm="."><plain>8.7±2.9 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="418" pm="."><plain>378 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="419" pm="."><plain>11.1±3.5 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="420" pm="."><plain>72 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" charoff="50"><text><SENT sid="421" pm="."><plain> MPR Cmax </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="422" pm="."><plain>8.8±3.1 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="423" pm="."><plain>384 </plain></SENT>
</text></td><td align="center" valign="top" char="±" charoff="50"><text><SENT sid="424" pm="."><plain>10.5±3.3 </plain></SENT>
</text></td><td align="center" valign="top" char="." charoff="50"><text><SENT sid="425" pm="."><plain>74 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><p>Abbreviations: AUC<sub>0–24</sub>, AUC from the time of dosing over a 0–24 h postdose time interval; <italic>C</italic><sub>24</sub>, observed plasma concentration at 24 h postdose; AUC<sub>inf</sub>, AUC from the time of dosing to the last measurable concentration and extrapolated to infinity; AUC<sub>last</sub>, area under the plasma drug concentration–time curve from the time of dosing to the last measurable concentration; <italic>C</italic><sub>max</sub>, maximum observed plasma concentration; MPR, metabolite to parent ratio of relevant PK parameter.</p></fn><fn id="t3-fn2"><p>Data shown as mean±s.d.</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
